Global Cell Therapy Biomanufacturing Market
Cell Therapy Biomanufacturing Market Report 2024: Market Revenue Data from 2022, Estimates for 2023, Forecasts for 2024 and Projected CAGRs through 2029
09 août 2024 05h41 HE | Research and Markets
Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapy Biomanufacturing Market 2024-2029" report has been added to ResearchAndMarkets.com's offering. The cell therapy biomanufacturing global...
phathom-pharmaceuticals-logo.jpg
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 08h00 HE | Phathom Pharmaceuticals
Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second...
Aclaris_Logo_CLR®.jpg
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
07 août 2024 07h00 HE | Aclaris Therapeutics, Inc.
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Thin-Bible-Paper-booklet_EN
World’s largest packaging and processing event has selected unique bible paper product as a finalist for the 2024 Technology Excellence Awards – the only European company in the category
07 août 2024 01h23 HE | ThinPrinting by St Michel Print
Pack Expo International has selected Unique medical leaflet - Thin Bible Paper Booklet as a finalist for the 2024 Technology Excellence Awards.
22157.jpg
Pharmaceutical Industry Net Zero Strategies Thematic Intelligence Report: Reduction Targets, Data, and Strategies of 18 Leading Pharmaceutical Companies
06 août 2024 10h11 HE | Research and Markets
Dublin, Aug. 06, 2024 (GLOBE NEWSWIRE) -- The "Thematic Intelligence: Net Zero Strategies in the Pharmaceutical Sector" report has been added to ResearchAndMarkets.com's offering. This report...
lumos.png
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
01 août 2024 16h05 HE | Lumos Pharma, Inc.
Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to...
Regeneron Logo.jpg
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
31 juil. 2024 07h30 HE | Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 12th annual Regeneron Prize for Creative Innovation (the...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
30 juil. 2024 16h30 HE | MannKind
MANNKIND CORPORATION TO HOLD 2024 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 7, 2024
Marius_logo_CMYK_no background.png
Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada
30 juil. 2024 09h30 HE | Marius Pharmaceuticals LLC
RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on developing innovative therapies for Testosterone Deficiency, is pleased to...
phathom-pharmaceuticals-logo.jpg
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
29 juil. 2024 07h59 HE | Phathom Pharmaceuticals
Management to host conference call on Thursday, August 8, 2024, at 8:30 am ET FLORHAM PARK, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...